FOLH1 and prostate cancer: conducted a randomized prospective trial to investigate the diagnostic performance of PET/MRI using dual-tracer [18F]FMC and [68Ga]Ga-PSMA-11 for predicting low vs. high lesion risk as well as BCR and overall patient risk with machine learning in primary prostate cancer patients (30).